COMMUNIQUÉS West-GlobeNewswire

LIfT BioSciences Announces Publication of Review Article in Frontiers in Immunology Highlighting Broad Therapeutic Potential of Neutrophils and IMANs in Cancer
22/04/2026
Neutrophils, long considered short-lived immune cells, can be therapeutically targeted when their appropriate subset and functional state are identified for the disease context LIfT BioSciences’ immunomodulatory alpha [...]
Mixlab and Instinct Partner to Transform Prescription Workflows for Veterinary Hospitals
22/04/2026
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- As veterinary hospitals manage growing clinical complexity and administrative demands, workflow efficiency remains a key priority for both patient outcomes and team [...]
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
22/04/2026
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms of multiple [...]
Aclarion Announces $2.5 Million Stock Repurchase Plan
22/04/2026
Highlights Disciplined Capital Allocation While Supporting Continued Nociscan® Adoption BROOMFIELD, Colo., April 22, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a [...]
The Beauty Health Company Announces Corporate Rebrand to SkinHealth Systems, Reflecting Evolution into a Clinically Driven, Science-Backed Medical Aesthetics Platform
22/04/2026
The Company will continue trading on the Nasdaq Capital Market under the ticker symbol “SKIN” LONG BEACH, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ: SKIN) today announced a corporate [...]
PMV Pharmaceuticals Announces Board Chair Transition
22/04/2026
Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new Chair PRINCETON, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “ [...]
Coave Therapeutics to present two posters at ARVO 2026, on first-in-class ligand-conjugated suprachoroidal vector and lead gene therapy program
22/04/2026
PARIS, France – 22 April 2026 : Coave Therapeutics (“Coave”), a company redefining targeted gene therapy with a best-in-class pipeline powered by ligand-conjugated vectors, today announces it will deliver two poster [...]
Microbot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®
22/04/2026
Members of the Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Represent the Largest Addressable User Market for the LIBERTY System At least [...]
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
22/04/2026
Ocular’s Investor Day will take place in New York City, with virtual access available, starting at 2:00 PM ET on Wednesday, June 17, 2026 BEDFORD, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. ( [...]
CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026
22/04/2026
Ongoing Phase 2 study in metastatic colorectal cancer (mCRC) demonstrates early clinical and biomarker activity with leronlimab in combination with TAS-102 and bevacizumab, supporting CCR5 as a therapeutic target [...]
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
22/04/2026
AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage : The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is interpreted within a [...]
Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026
22/04/2026
CAMBRIDGE, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
22/04/2026
- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale - - Effects seen on both daily function and neurological examination, consistent with previously reported [...]
Repligen to Report First Quarter 2026 Financial Results
22/04/2026
Webcast and Conference Call to Be Held Tuesday, May 5, 2026, at 8:00 a.m. ET WALTHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first [...]
Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026
22/04/2026
FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that [...]
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
22/04/2026
Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs Presentations reinforce potential of degraders to overcome limitations of inhibitors and expand therapeutic reach [...]
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
22/04/2026
VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
SRx Health Solutions Invests in Astro Investment XVII, an Affiliate of Astro Capital
22/04/2026
Company has invested greater than 10% of its investable capital in the convergence of Artificial Intelligence (“AI”) and space through Astro Capital NORTH PALM BEACH, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- SRx Health [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
22/04/2026
PALO ALTO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today [...]

Pages